Third Rock Ventures launches Ember Therapeutics

Third Rock Ventures LLC, a venture capital firm with offices in Boston, announced the formation of Ember Therapeutics with a $34 million Series A financing.

In a press release, Ember said it looks to leverage findings in brown-fat biology and recent breakthroughs in selective insulin sensitivity to develop treatments for metabolic diseases, including Type 2 diabetes and obesity.

The plan is for some of Ember’s early drug candidates to “augment and activate the body’s brown fat, amplifying the natural ability to efficiently burn fuel stores such as glucose and lipids to reduce stored calories in the body,’’ the release said. 


Ember’s founders are Bruce Spiegelman, a professor of cell biology at Dana Farber Cancer Institute and Harvard Medical School; Patrick Griffin, chairman and professor of the department of molecular therapeutics at the Scripps Research Institute; and C. Ronald Kahn, M.D., professor of medicine at the Joslin Diabetes Center and the Harvard Medical School, along with Third Rock Ventures, the company said.

Ember’s interim chief executive is Louis Tartaglia, a partner at Third Rock Ventures.

Jump To Comments